PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $104,833,223 | -27.6% | 10,109,279 | 0.0% | 6.96% | -19.5% |
Q2 2023 | $144,764,875 | +141.2% | 10,109,279 | +20.2% | 8.64% | +98.9% |
Q1 2023 | $60,027,065 | -36.4% | 8,407,152 | 0.0% | 4.35% | -25.9% |
Q4 2022 | $94,328,245 | +1.3% | 8,407,152 | 0.0% | 5.86% | -18.2% |
Q3 2022 | $93,151,000 | +89.4% | 8,407,152 | +44.3% | 7.17% | +54.6% |
Q2 2022 | $49,183,000 | -38.0% | 5,827,415 | 0.0% | 4.64% | -31.3% |
Q1 2022 | $79,311,000 | – | 5,827,415 | – | 6.76% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |